2020 Q4 Form 10-Q Financial Statement

#000135657620000076 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $143.6M $155.1M $102.1M
YoY Change 42.96% 51.88% -0.83%
Cost Of Revenue $18.50M $21.39M $4.819M
YoY Change 351.22% 343.83% 14.55%
Gross Profit $125.0M $133.7M $97.32M
YoY Change 29.8% 37.43% -1.49%
Gross Profit Margin 87.05% 86.21% 95.28%
Selling, General & Admin $56.20M $54.46M $39.34M
YoY Change 57.42% 38.42% -3.79%
% of Gross Profit 44.96% 40.72% 40.43%
Research & Development $17.90M $16.84M $16.94M
YoY Change -9.6% -0.61% -17.04%
% of Gross Profit 14.32% 12.59% 17.41%
Depreciation & Amortization $5.500M $7.600M $1.600M
YoY Change 223.53% 375.0% -15.79%
% of Gross Profit 4.4% 5.68% 1.64%
Operating Expenses $82.00M $71.30M $56.29M
YoY Change 47.75% 26.67% -8.2%
Operating Profit $43.00M $56.14M $39.73M
YoY Change 5.35% 41.31% 6.01%
Interest Expense $700.0K $6.088M $5.662M
YoY Change -121.21% 7.52% 5562.0%
% of Operating Profit 1.63% 10.84% 14.25%
Other Income/Expense, Net -$4.000M -$3.429M -$139.0K
YoY Change -217.65% 2366.91% -87.41%
Pretax Income $39.70M $52.71M $39.59M
YoY Change -2.93% 33.14% 8.85%
Income Tax $8.900M $12.71M $10.73M
% Of Pretax Income 22.42% 24.12% 27.1%
Net Earnings $30.80M $40.00M $28.86M
YoY Change -7.03% 38.59% 3.03%
Net Earnings / Revenue 21.45% 25.78% 28.26%
Basic Earnings Per Share $0.76 $0.55
Diluted Earnings Per Share $572.5K $0.74 $0.54
COMMON SHARES
Basic Shares Outstanding 52.69M shares 52.66M shares 52.45M shares
Diluted Shares Outstanding 53.76M shares 53.81M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $422.5M $352.0M $296.7M
YoY Change 21.72% 18.64% 5.89%
Cash & Equivalents $288.6M $204.3M $116.9M
Short-Term Investments $133.9M $147.7M $179.8M
Other Short-Term Assets $18.70M $24.50M $18.20M
YoY Change 61.21% 34.62% 95.7%
Inventory $48.33M $42.47M $25.50M
Prepaid Expenses
Receivables $140.9M $133.1M $86.70M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $630.4M $552.0M $427.1M
YoY Change 33.38% 29.25% 9.34%
LONG-TERM ASSETS
Property, Plant & Equipment $37.82M $17.40M $9.977M
YoY Change 121.61% 74.35% 44.59%
Goodwill $77.91M $89.14M
YoY Change
Intangibles $364.3M $402.3M $26.10M
YoY Change 1366.76% 1441.19%
Long-Term Investments $350.4M $388.2M $596.4M
YoY Change -40.79% -34.91% 29.57%
Other Assets $43.25M $18.32M $574.0K
YoY Change 97.54% 3092.33% -98.21%
Total Long-Term Assets $873.7M $958.0M $679.8M
YoY Change 27.06% 40.92% 27.81%
TOTAL ASSETS
Total Short-Term Assets $630.4M $552.0M $427.1M
Total Long-Term Assets $873.7M $958.0M $679.8M
Total Assets $1.504B $1.510B $1.107B
YoY Change 29.63% 36.42% 19.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.147M $11.19M $3.090M
YoY Change -39.38% 262.23% -68.47%
Accrued Expenses $78.93M $197.0M $138.9M
YoY Change 58.78% 41.83% 17.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.600M
YoY Change
Total Short-Term Liabilities $245.1M $299.6M $149.7M
YoY Change 52.63% 100.11% 8.26%
LONG-TERM LIABILITIES
Long-Term Debt $361.8M $376.8M $341.2M
YoY Change 4.81% 10.43% 4.76%
Other Long-Term Liabilities $42.79M $9.304M $11.21M
YoY Change 49.32% -17.01% -69.37%
Total Long-Term Liabilities $42.79M $9.304M $11.21M
YoY Change 49.32% -17.01% -96.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $245.1M $299.6M $149.7M
Total Long-Term Liabilities $42.79M $9.304M $11.21M
Total Liabilities $759.2M $801.1M $549.7M
YoY Change 34.41% 45.75% 9.8%
SHAREHOLDERS EQUITY
Retained Earnings $326.5M $295.7M $166.4M
YoY Change 63.62% 77.7%
Common Stock $53.00K $53.00K $52.00K
YoY Change 0.0% 1.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $744.9M $708.9M $557.3M
YoY Change
Total Liabilities & Shareholders Equity $1.504B $1.510B $1.107B
YoY Change 29.63% 36.42% 19.99%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $30.80M $40.00M $28.86M
YoY Change -7.03% 38.59% 3.03%
Depreciation, Depletion And Amortization $5.500M $7.600M $1.600M
YoY Change 223.53% 375.0% -15.79%
Cash From Operating Activities $31.90M $5.600M $37.60M
YoY Change -27.17% -85.11% -39.74%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$100.0K -$500.0K
YoY Change -90.0% -80.0% 400.0%
Acquisitions
YoY Change
Other Investing Activities $49.50M -$11.10M -$7.900M
YoY Change 130.23% 40.51% -130.98%
Cash From Investing Activities $49.30M -$11.30M -$8.400M
YoY Change 152.82% 34.52% -133.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.100M -1.000M 300.0K
YoY Change 158.33% -433.33% -62.5%
NET CHANGE
Cash From Operating Activities 31.90M 5.600M 37.60M
Cash From Investing Activities 49.30M -11.30M -8.400M
Cash From Financing Activities 3.100M -1.000M 300.0K
Net Change In Cash 84.30M -6.700M 29.50M
YoY Change 30.7% -122.71% -66.67%
FREE CASH FLOW
Cash From Operating Activities $31.90M $5.600M $37.60M
Capital Expenditures -$200.0K -$100.0K -$500.0K
Free Cash Flow $32.10M $5.700M $38.10M
YoY Change -29.91% -85.04% -39.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001356576
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35518
dei Entity Registrant Name
EntityRegistrantName
SUPERNUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2590184
dei Entity Address Address Line1
EntityAddressAddressLine1
9715 Key West Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
838-2500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52685121 shares
dei Trading Symbol
TradingSymbol
SUPN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204293000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181381000 USD
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
147657000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165692000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
133107000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
87332000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
42465000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
26628000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24493000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11611000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
552015000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
472644000 USD
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
388185000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
591773000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17395000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17068000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21019000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21279000 USD
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
21676000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
402265000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24840000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
89143000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
0 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
32063000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18324000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
615000 USD
CY2020Q3 us-gaap Assets
Assets
1510022000 USD
CY2019Q4 us-gaap Assets
Assets
1160282000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
11193000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10141000 USD
CY2020Q3 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
136973000 USD
CY2019Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107629000 USD
CY2020Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
56289000 USD
CY2019Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
34305000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
82900000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0 USD
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2443000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3741000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2825000 USD
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3612000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 USD
CY2020Q3 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
4898000 USD
CY2019Q4 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
3244000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
299606000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
160587000 USD
CY2020Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
357521000 USD
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
345170000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
33000000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 USD
CY2020Q3 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
14960000 USD
CY2019Q4 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
19248000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29522000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30440000 USD
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19289000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 USD
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
37941000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9304000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9409000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
801143000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
564854000 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52670121 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52670121 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52533348 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52533348 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
403396000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
388410000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9700000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7417000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
295730000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
199548000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
708879000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
595428000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1510022000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1160282000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
155135000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102140000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
376840000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
292309000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
21388000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4819000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33926000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12547000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16839000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16943000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58023000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49307000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54660000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39343000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
144377000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
118782000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6108000 USD
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1306000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9814000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3918000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
98995000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
62411000 USD
us-gaap Costs And Expenses
CostsAndExpenses
246140000 USD
us-gaap Costs And Expenses
CostsAndExpenses
184554000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
56140000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
39729000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
130700000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
107755000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3262000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5559000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
12988000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
15696000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
6088000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
5662000 USD
us-gaap Interest Expense
InterestExpense
17658000 USD
us-gaap Interest Expense
InterestExpense
16930000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-603000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-36000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2925000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3429000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-139000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1745000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1180000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
52711000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
39590000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
128955000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
106575000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12714000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10730000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32773000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26648000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
39997000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
us-gaap Net Income Loss
NetIncomeLoss
96182000 USD
us-gaap Net Income Loss
NetIncomeLoss
79927000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52658850 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52453384 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52583891 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52392232 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53762642 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53805838 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53663273 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53898486 shares
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
39997000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
us-gaap Net Income Loss
NetIncomeLoss
96182000 USD
us-gaap Net Income Loss
NetIncomeLoss
79927000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1659000 USD
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1337000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2283000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10419000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1659000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1337000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2283000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
10419000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
38338000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
30197000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
98465000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
90346000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
595428000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3988000 USD
CY2020Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
32000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
21518000 USD
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-7583000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
613383000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4962000 USD
CY2020Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
1437000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
34667000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
11525000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
665974000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4490000 USD
CY2020Q3 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
77000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
39997000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1659000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
708879000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
453023000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3287000 USD
CY2019Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
783000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18340000 USD
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4585000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
480018000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4022000 USD
CY2019Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
1640000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4497000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
522904000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3914000 USD
CY2019Q3 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
242000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1337000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
557257000 USD
us-gaap Profit Loss
ProfitLoss
96182000 USD
us-gaap Profit Loss
ProfitLoss
79927000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13440000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11223000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12621000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5029000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3217000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3058000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12351000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11701000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
3636000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
131000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
200000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
4515000 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
4331000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
6320000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
5028000 USD
supn Noncash Operating Lease Cost
NoncashOperatingLeaseCost
2599000 USD
supn Noncash Operating Lease Cost
NoncashOperatingLeaseCost
2600000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-280000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1689000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26840000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16344000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5437000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-155000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
9318000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
4236000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2416000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
141000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1527000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-334000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
21166000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
-9013000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8410000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1120000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2538000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-7559000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3489000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1903000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
106466000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
99338000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
297200000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 USD
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
87890000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
361121000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
319421000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
184467000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3234000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
707000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
141000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-84044000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-177362000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1056000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1546000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2665000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
490000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2665000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22912000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75359000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181381000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192248000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
204293000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116889000 USD
us-gaap Interest Paid Net
InterestPaidNet
2516000 USD
us-gaap Interest Paid Net
InterestPaidNet
2516000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
42284000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
35933000 USD
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
115900000 USD
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
0 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
352000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
495000 USD
supn Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
0 USD
supn Property And Equipment Acquired Under Build To Suit Lease Transaction
PropertyAndEquipmentAcquiredUnderBuildToSuitLeaseTransaction
387000 USD
supn Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
25225000 USD
supn Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
31856000 USD
us-gaap Nature Of Operations
NatureOfOperations
Organization and Business<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware, commencing operations in 2005. The Company is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, marketing five products, including: Oxtellar XR for the treatment of epilepsy; Trokendi XR for the prophylaxis of migraine headache and the treatment of epilepsy; APOKYN and XADAGO for the treatment of Parkinson's disease; and MYOBLOC for the treatment of cervical dystonia and sialorrhea. The Company is also developing multiple proprietary CNS product candidates to address significant unmet medical needs and market opportunities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched Oxtellar XR and Trokendi XR for the treatment of epilepsy in 2013, followed by the launch of Trokendi XR for the prophylaxis of migraine headache in adolescents and adults in 2017. The Company launched Oxtellar XR with an expanded indication, including monotherapy for partial seizures in January 2019. On June 9, 2020, the Company completed the acquisition of the CNS portfolio of US WorldMeds Partners, LLC (USWM Acquisition). With the acquisition, the Company acquired the right to further develop and commercialize three marketed products, as well as a product candidate in late-stage development. Refer to Note 3 for further discussion on the USWM Acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations, and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of September 30, 2020. Through the first nine months of 2020, the pandemic has had limited effect on the Company's business operations, and no material impact on its condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.</span></div>
supn Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
5 marketProduct
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reclassifications</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts in the condensed consolidated statements of earnings have been reclassified to conform to the current year presentation, including a reclassification made to separately present amortization of intangible assets. This was previously included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and now is recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statements of earnings. These reclassifications had no effect on operating earnings or on our other condensed consolidated financial statements for the three and nine months ended September 30, 2020 and 2019.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div>
supn Sales Return Period Prior To Expiration
SalesReturnPeriodPriorToExpiration
P6M
supn Sales Return Period
SalesReturnPeriod
P12M
supn Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
5 product
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
supn Business Acquisition Transaction Costs Adjustment
BusinessAcquisitionTransactionCostsAdjustment
10100000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
155135000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102140000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
376840000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
292309000 USD
CY2020Q3 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
2400000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
6300000 USD
CY2019Q3 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
1600000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
5000000.0 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
522920000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
747598000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13835000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10031000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
913000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
164000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
535842000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
757465000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
147657000 USD
CY2020Q3 supn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
142272000 USD
CY2020Q3 supn Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
136095000 USD
CY2020Q3 supn Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
109818000 USD
CY2020Q3 supn Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
0 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
535842000 USD
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11223000 USD
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4490000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3914000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13440000 USD
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
39997000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
28860000 USD
us-gaap Net Income Loss
NetIncomeLoss
96182000 USD
us-gaap Net Income Loss
NetIncomeLoss
79927000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52658850 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52453384 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52583891 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52392232 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1103792 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1352454 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1079382 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1506254 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53762642 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53805838 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53663273 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53898486 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.53
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.48
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12714000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10730000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32773000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26648000 USD
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.241
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.271
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.254
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.250
CY2020Q3 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
11100000 USD
CY2019Q4 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
11000000.0 USD
CY2020Q3 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
9528000 USD
CY2019Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
4582000 USD
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17571000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11428000 USD
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15366000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10618000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
42465000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
26628000 USD
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31907000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29767000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14512000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12699000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17395000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17068000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1800000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000 USD
CY2020Q3 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
1000000.0 USD
CY2020Q3 us-gaap Goodwill Gross
GoodwillGross
89143000 USD
CY2019Q4 us-gaap Goodwill Gross
GoodwillGross
0 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
28348000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18535000 USD
CY2020Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
402265000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
24840000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9800000 USD
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3900000 USD
CY2020Q3 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
6264000 USD
CY2019Q4 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
13285000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14892000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11223000 USD
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2627000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3936000 USD
CY2020Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
14678000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17828000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5861000 USD
CY2020Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
56289000 USD
CY2019Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
34305000 USD
CY2020Q3 supn Accrued Rebates
AccruedRebates
110543000 USD
CY2019Q4 supn Accrued Rebates
AccruedRebates
88811000 USD
CY2020Q3 supn Accrued Product Returns
AccruedProductReturns
26430000 USD
CY2019Q4 supn Accrued Product Returns
AccruedProductReturns
18818000 USD
CY2020Q3 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
136973000 USD
CY2019Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107629000 USD
CY2019Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4000000.0 USD
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4945000 USD
CY2019Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4546000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
14430000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
13518000 USD
CY2020Q3 us-gaap Interest Expense Other
InterestExpenseOther
1143000 USD
CY2019Q3 us-gaap Interest Expense Other
InterestExpenseOther
1116000 USD
us-gaap Interest Expense Other
InterestExpenseOther
3228000 USD
us-gaap Interest Expense Other
InterestExpenseOther
3412000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
6088000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
5662000 USD
us-gaap Interest Expense
InterestExpense
17658000 USD
us-gaap Interest Expense
InterestExpense
16930000 USD
CY2020Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4200000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12400000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11700000 USD
CY2014Q3 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
30000000.0 USD

Files In Submission

Name View Source Status
0001356576-20-000076-index-headers.html Edgar Link pending
0001356576-20-000076-index.html Edgar Link pending
0001356576-20-000076.txt Edgar Link pending
0001356576-20-000076-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
supn-20200930.htm Edgar Link pending
supn-20200930.xsd Edgar Link pending
supn-20200930x10qxex311.htm Edgar Link pending
supn-20200930x10qxex312.htm Edgar Link pending
supn-20200930x10qxex321.htm Edgar Link pending
supn-20200930x10qxex322.htm Edgar Link pending
supn-20200930_cal.xml Edgar Link unprocessable
supn-20200930_def.xml Edgar Link unprocessable
supn-20200930_g1.jpg Edgar Link pending
supn-20200930_htm.xml Edgar Link completed
supn-20200930_lab.xml Edgar Link unprocessable
supn-20200930_pre.xml Edgar Link unprocessable